Profile and correlates of colorimetric reagent kit use among people who use ecstasy/MDMA and other illegal stimulants in Australia, 2019-2021

Daisy Gibbs1, Amy Peacock1,2, Olivia Price1, Monica J. Barratt3,1, Nadine Ezard1,4,5, Rachel Sutherland1, Penelope L. Hilly1,4,6,7, Jodie Grigg8, Simon Lenton1,8, Robert Page1,5, Caroline Salom1,9, Caitlin Hughes1,10, & Raimondo Bruno1,2

1National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia, 2School of Psychological Sciences, University of Tasmania, Hobart, Australia, 3Social and Global Studies Centre and Digital Ethnography Research Centre, RMIT University, Melbourne, Australia, 4National Centre for Clinical Research on Emerging Drugs, Sydney, Australia, 5St Vincent’s Hospital, Sydney, Australia, 6Behaviours and Health Risks Program, Burnet Institute, Melbourne, Australia, 7School of Public Health and Preventative Medicine, Monash University, Melbourne, Australia, 8National Drug Research Institute, Curtin University, Perth, Australia, 9Institute for Social Science Research, The University of Queensland, Brisbane, Australia, 10Centre for Crime Policy and Research, Flinders University, Adelaide, Australia

Presenter’s email: daisy.gibbs@unsw.edu.au

Introduction: Colorimetric reagent kits can provide information about the presence or absence of a nominated substance in drug samples. We aimed to identify patterns and correlates of colorimetric reagent kit use, as well as behavioural outcomes of testing, among people who use illegal stimulants in a context lacking permanent government-sanctioned drug checking services.

Method: Australians residing in capital cities who reported monthly or more frequent use of ecstasy/MDMA and/or other illegal stimulants in the past six months were interviewed about testing the contents and/or purity of illegal drugs, and features of last colorimetric reagent kit use. Logistic regression identified correlates of last using a testing kit.

Key Findings: Of 2403 participants, 34% reported testing drug contents and/or purity in the last year; of whom, 86% last used a colorimetric reagent kit. On the last occasion, 48% tested a substance received as MDMA; of these 87% detected MDMA. Of those who expected and detected MDMA, 66% and 29% reported this finding to their friends and dealer, respectively. Factors associated with use of drug checking include younger age (adjusted odds-ratio 1.77; 95% confidence-interval 1.35-.33), being male (1.61; 1.25-2.07), weekly MDMA use (1.4; 1.03-1.89), and daily cannabis use (1.55; 1.12-2.44).

Discussions and Conclusions: In the absence of permanent government-sanctioned drug checking services, it is important to acknowledge that people who use illegal stimulants seek out objective information about the contents of their illicit drugs and already engage in drug checking practices. However, predominant technologies employed are suboptimal, lacking tailored specialist advice and education.

Disclosure of Interest Statement: EDRS, the National Drug and Alcohol Research Centre, the National Drug Research Institute and National Centre for Clinical Research in Emerging Drugs are supported by funding from the Australian Government Department of Health under the Drug and Alcohol Program. AP has received untied educational grants from Seqirus and Mundipharma. RS has received untied educational grants from Seqirus. RB has received untied educational grants from Mundipharma and Indivior. SL has served as an unpaid member of an Advisory Board for Mundipharma. Funding from these organisations has now ceased, funding was for work unrelated to this project, and the funding bodies had no role in study design, analysis and reporting. No pharmaceutical grants were received for this study. NE is employed by St Vincent’s Hospital in the NSW Health public health service.